It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Targeted therapies and immunotherapy are improving leukemia survival rates, offering renewed hope for more effective ...
Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...
From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care ...
The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF). This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results